This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 7345 |
virus infection | 5550 |
influenza viruses | 3043 |
respiratory tract | 2796 |
respiratory syncytial | 2752 |
rna viruses | 2699 |
immune response | 2694 |
syncytial virus | 2632 |
respiratory syndrome | 2624 |
acute respiratory | 2527 |
avian influenza | 2303 |
infected cells | 2196 |
ebola virus | 2159 |
virus replication | 2151 |
viral rna | 2057 |
immune responses | 1979 |
respiratory viruses | 1927 |
amino acid | 1890 |
viral infections | 1875 |
viral replication | 1772 |
host cell | 1764 |
viral infection | 1705 |
cell culture | 1613 |
united states | 1607 |
severe acute | 1589 |
virus type | 1569 |
immunodeficiency virus | 1519 |
public health | 1516 |
virus infections | 1506 |
herpes simplex | 1494 |
epithelial cells | 1448 |
type i | 1431 |
infectious diseases | 1418 |
dengue virus | 1382 |
west nile | 1372 |
antiviral activity | 1357 |
infl uenza | 1314 |
simplex virus | 1297 |
zika virus | 1293 |
immune system | 1284 |
innate immune | 1272 |
virus particles | 1265 |
vaccinia virus | 1235 |
cord uid | 1203 |
doc id | 1203 |
gene expression | 1188 |
cell lines | 1171 |
viral proteins | 1165 |
nile virus | 1159 |
nucleic acid | 1146 |
human immunodeficiency | 1131 |
rna virus | 1123 |
disease virus | 1122 |
clinical signs | 1112 |
hemorrhagic fever | 1092 |
fever virus | 1082 |
syndrome coronavirus | 1032 |
viral genome | 1021 |
may also | 1010 |
lower respiratory | 996 |
rna polymerase | 975 |
pandemic influenza | 973 |
electron microscopy | 956 |
cell surface | 948 |
highly pathogenic | 947 |
host cells | 904 |
hong kong | 902 |
neutralizing antibodies | 886 |
nervous system | 872 |
stranded rna | 852 |
encephalitis virus | 837 |
enveloped viruses | 827 |
nipah virus | 805 |
animal models | 804 |
sialic acid | 794 |
clinical trials | 791 |
amino acids | 789 |
influenza vaccine | 773 |
virus entry | 770 |
chain reaction | 765 |
measles virus | 760 |
respiratory virus | 752 |
polymerase chain | 747 |
membrane fusion | 740 |
infectious bronchitis | 737 |
dna viruses | 732 |
respiratory disease | 731 |
respiratory infections | 726 |
closely related | 714 |
seasonal influenza | 709 |
middle east | 705 |
monoclonal antibodies | 704 |
like particles | 698 |
upper respiratory | 696 |
viral load | 690 |
human influenza | 684 |
plasma membrane | 683 |
syndrome virus | 680 |
enteric viruses | 674 |
central nervous | 669 |
cell cultures | 660 |
mosaic virus | 654 |
structural proteins | 650 |
viral particles | 650 |
dendritic cells | 646 |
host range | 641 |
world health | 629 |
virus disease | 625 |
yellow fever | 613 |
young children | 611 |
human metapneumovirus | 608 |
infectious virus | 607 |
cell line | 606 |
cell death | 606 |
reverse transcription | 604 |
influenza infection | 603 |
vesicular stomatitis | 602 |
nucleic acids | 600 |
life cycle | 589 |
hepatitis virus | 588 |
virus strains | 583 |
rabies virus | 581 |
antiviral drugs | 581 |
receptor binding | 581 |
rna replication | 580 |
innate immunity | 580 |
infectious disease | 576 |
east respiratory | 574 |
health organization | 572 |
parainfluenza virus | 567 |
porcine reproductive | 567 |
newcastle disease | 564 |
diarrhea virus | 561 |
virus rna | 559 |
bronchitis virus | 558 |
vaccine development | 558 |
rna synthesis | 557 |
viral diseases | 552 |
stomatitis virus | 549 |
live attenuated | 548 |
novel coronavirus | 545 |
disease severity | 545 |
tissue culture | 545 |
virus detection | 543 |
severe disease | 541 |
viral protein | 538 |
virus vaccine | 533 |
influenza vaccines | 528 |
sars coronavirus | 526 |
time pcr | 525 |
viral genomes | 521 |
phylogenetic analysis | 520 |
monoclonal antibody | 520 |
tract infections | 519 |
reverse transcriptase | 518 |
host factors | 517 |
human coronavirus | 507 |
valley fever | 502 |
mouse model | 502 |
important role | 502 |
rift valley | 502 |
strand rna | 500 |
risk factors | 499 |
dependent rna | 496 |
endoplasmic reticulum | 491 |
virus genome | 490 |
human respiratory | 490 |
host immune | 489 |
incubation period | 485 |
class i | 483 |
vero cells | 482 |
chikungunya virus | 482 |
reverse genetics | 481 |
infected mice | 478 |
capsid protein | 478 |
protein synthesis | 477 |
binding site | 476 |
antiviral agents | 469 |
viral entry | 468 |
cell responses | 467 |
rsv infection | 463 |
japanese encephalitis | 461 |
genetic diversity | 458 |
spike protein | 457 |
virus transmission | 455 |
pathogenic avian | 454 |
respiratory viral | 454 |
viral pathogens | 453 |
antibody responses | 453 |
swine influenza | 450 |
antibody response | 448 |
respiratory illness | 446 |
virus isolation | 445 |
influenza pandemic | 445 |
mouse hepatitis | 441 |
neutralizing antibody | 437 |
infected patients | 434 |
wide range | 431 |
binding protein | 429 |
viral envelope | 423 |
human infection | 423 |
disease control | 423 |
virus strain | 422 |
cell membrane | 420 |
high levels | 419 |
viral dna | 418 |
cleavage site | 414 |
mammalian cells | 414 |
hendra virus | 412 |
saudi arabia | 409 |
adaptive immune | 409 |
endothelial cells | 408 |
large number | 407 |
protective immunity | 406 |
i interferon | 405 |
rna genome | 401 |
host species | 400 |
cell types | 396 |
i ifn | 396 |
sendai virus | 396 |
virus vaccines | 395 |
health care | 394 |
target cells | 394 |
clinical disease | 392 |
viruses may | 391 |
direct contact | 390 |
emerging viruses | 390 |
recent studies | 389 |
fusion protein | 389 |
may occur | 388 |
leukemia virus | 387 |
respiratory infection | 386 |
infected animals | 385 |
common cold | 385 |
mouth disease | 384 |
infectious agents | 382 |
marburg virus | 381 |
emerging infectious | 380 |
antiviral effect | 380 |
barr virus | 376 |
bone marrow | 375 |
even though | 375 |
experimental infection | 373 |
guinea pigs | 373 |
cells infected | 371 |
previously described | 371 |
human transmission | 371 |
protein kinase | 371 |
many viruses | 370 |
lymph nodes | 369 |
uenza virus | 368 |
plant viruses | 366 |
porcine epidemic | 366 |
viruses isolated | 366 |
human disease | 366 |
virus isolates | 365 |
open reading | 362 |
fruit bats | 362 |
systematic review | 361 |
sequence analysis | 360 |
human population | 358 |
escherichia coli | 358 |
room temperature | 358 |
sindbis virus | 356 |
clinical trial | 353 |
recent study | 352 |
nucleotide sequence | 352 |
bovine viral | 350 |
inflammatory response | 350 |
specific antibodies | 350 |
gene therapy | 349 |
borne encephalitis | 348 |
highly conserved | 345 |
envelope protein | 345 |
epidemic diarrhea | 344 |
virus may | 341 |
ns protein | 341 |
animal model | 341 |
host proteins | 341 |
persistent infection | 341 |
swine fever | 341 |
rna interference | 340 |
north america | 339 |
viral antigens | 339 |
mg kg | 337 |
virus evolution | 335 |
human health | 334 |
side effects | 334 |
associated virus | 332 |
virus particle | 332 |
developing countries | 332 |
different viruses | 330 |
molecular biology | 329 |
pregnant women | 329 |
clinical samples | 328 |
human rhinovirus | 328 |
infected cell | 328 |
virus ns | 328 |
recent years | 324 |
widely used | 324 |
tract infection | 323 |
genome sequence | 322 |
like receptor | 321 |
envelope glycoprotein | 320 |
semliki forest | 319 |
reading frame | 316 |
genetic material | 316 |
nonstructural protein | 315 |
transplant recipients | 314 |
mice infected | 314 |
genomic rna | 314 |
hiv infection | 312 |
causative agent | 311 |
cell entry | 310 |
present study | 310 |
drug resistance | 310 |
forest virus | 309 |
antiviral therapy | 308 |
nonhuman primates | 307 |
host response | 307 |
pcr assays | 307 |
structural protein | 306 |
complete genome | 305 |
capsid proteins | 305 |
like viruses | 303 |
weight loss | 302 |
human viruses | 302 |
respiratory distress | 301 |
clinical symptoms | 301 |
performed using | 301 |
virus hemagglutinin | 301 |
pcr assay | 301 |
acid sequence | 300 |
feline immunodeficiency | 300 |
two different | 299 |
stranded dna | 298 |
virus glycoprotein | 297 |
mhc class | 297 |
viral diarrhea | 296 |
viral respiratory | 296 |
immune cells | 294 |
nucleocapsid protein | 294 |
mortality rate | 294 |
antiviral drug | 293 |
peripheral blood | 291 |
wild birds | 290 |
equine encephalitis | 290 |
human cases | 290 |
new virus | 288 |
years old | 288 |
virus titers | 286 |
antiviral response | 286 |
low ph | 286 |
infection may | 286 |
sense rna | 284 |
viral disease | 284 |
zoonotic viruses | 283 |
type ii | 283 |
west africa | 282 |
least one | 282 |
chronic hepatitis | 281 |
experimentally infected | 281 |
bat species | 280 |
time rt | 280 |
fusion peptide | 280 |
animal viruses | 280 |
infected individuals | 279 |
membrane protein | 279 |
borna disease | 278 |
also found | 277 |
pathogenic viruses | 276 |
hcv infection | 276 |
spectrum antiviral | 276 |
human papillomavirus | 275 |
infection control | 275 |
human infections | 275 |
necrosis factor | 275 |
congo hemorrhagic | 274 |
several studies | 273 |
replication cycle | 272 |
viral antigen | 272 |
antibody titers | 272 |
respiratory symptoms | 272 |
binding sites | 272 |
clinical features | 270 |
human cells | 270 |
matrix protein | 270 |
commonly used | 270 |
molecular mechanisms | 269 |
human cytomegalovirus | 269 |
canine distemper | 265 |
genome replication | 265 |
phase i | 264 |
genome sequences | 264 |
viral nucleic | 264 |
mdck cells | 263 |
lassa fever | 262 |
otitis media | 262 |
crystal structure | 261 |
tobacco mosaic | 260 |
may lead | 260 |
viral gene | 260 |
another study | 260 |
binding domain | 258 |
lymphocytic choriomeningitis | 257 |
length cov | 256 |
virsorter node | 256 |
node length | 256 |
bacterial infections | 256 |
virus isolated | 256 |
ion channel | 256 |
human parainfluenza | 256 |
multiple sclerosis | 256 |
nk cells | 255 |
cellular immune | 255 |
relative humidity | 253 |
also known | 252 |
human coronaviruses | 252 |
translation initiation | 250 |
naturally occurring | 249 |
cellular proteins | 249 |
vaccine candidates | 249 |
viral sequences | 247 |
antiviral effects | 247 |
nonstructural proteins | 246 |
acid residues | 246 |
hela cells | 246 |
borne viruses | 246 |
like illness | 246 |
may result | 246 |
clinical specimens | 245 |
heat shock | 245 |
new host | 244 |
stem cell | 244 |
high risk | 243 |
species transmission | 243 |
tumor necrosis | 243 |
viral shedding | 243 |
previous studies | 242 |
coronavirus infection | 241 |
cat virsorter | 241 |
haemorrhagic fever | 240 |
virus shedding | 240 |
may cause | 239 |
immunocompromised patients | 239 |
lipid rafts | 239 |
immune evasion | 239 |
dna polymerase | 238 |
class ii | 238 |
vaccine strain | 238 |
acid sequences | 237 |
drinking water | 237 |
like virus | 236 |
rna recombination | 236 |
days post | 235 |
viral vectors | 234 |
pandemic virus | 234 |
plant virus | 234 |
parainfluenza viruses | 234 |
blood cells | 234 |
animal species | 234 |
host interactions | 232 |
wild type | 232 |
high mortality | 231 |
silver nanoparticles | 231 |
related viruses | 231 |
replication complex | 231 |
severe respiratory | 231 |
coronavirus disease | 230 |
increased risk | 230 |
intensive care | 230 |
vaccine candidate | 229 |
influenza vaccination | 229 |
authors declare | 229 |
new york | 228 |
generation sequencing | 228 |
sequence data | 228 |
age groups | 227 |
guinea pig | 227 |
infected cats | 227 |
mortality rates | 227 |
choriomeningitis virus | 226 |
venezuelan equine | 226 |
virus genomes | 226 |
type iii | 226 |
envelope proteins | 225 |
zoster virus | 225 |
years ago | 225 |
cytopathic effect | 225 |
mononuclear cells | 225 |
mutation rate | 224 |
virus inactivation | 224 |
infect humans | 224 |
human bocavirus | 224 |
target cell | 224 |
growth factor | 224 |
lipid bilayer | 223 |
type virus | 223 |
virus challenge | 223 |
mutation rates | 223 |
reading frames | 223 |
additional file | 222 |
natural killer | 222 |
respiratory pathogens | 222 |
viral clearance | 222 |
control group | 222 |
age group | 221 |
inflammatory cytokines | 221 |
virus envelope | 220 |
virus families | 220 |
cause disease | 219 |
fatality rate | 218 |
signaling pathway | 218 |
fusion proteins | 217 |
domestic animals | 217 |
protein expression | 217 |
linked immunosorbent | 217 |
pulmonary disease | 216 |
gene products | 216 |
acute infection | 216 |
natural infection | 216 |
nucleotide sequences | 216 |
controlled trial | 215 |
asthma exacerbations | 215 |
serum samples | 215 |
virus proteins | 215 |
transcription factor | 214 |
stem cells | 214 |
wide variety | 214 |
human airway | 213 |
envelope glycoproteins | 212 |
viral pathogenesis | 212 |
low levels | 212 |
currently available | 212 |
novel viruses | 211 |
viral particle | 211 |
tract disease | 211 |
tissue tropism | 211 |
first time | 211 |
like receptors | 211 |
molecular weight | 210 |
naturally infected | 209 |
clinical manifestations | 208 |
per year | 208 |
herpes virus | 208 |
laboratory mice | 208 |
viral loads | 208 |
determine whether | 207 |
transcription factors | 207 |
described previously | 207 |
human monoclonal | 207 |
spinal cord | 206 |
recombinant viruses | 206 |
close contact | 206 |
norwalk virus | 206 |
cell fusion | 206 |
antiviral activities | 206 |
secondary bacterial | 206 |
viral genes | 206 |
rhesus macaques | 205 |
control measures | 205 |
cov infection | 205 |
cell response | 205 |
antigenic drift | 205 |
recombinant virus | 204 |
membrane proteins | 204 |
two viruses | 204 |
disease progression | 204 |
neuraminidase inhibitors | 203 |
virus production | 203 |
viral glycoproteins | 203 |
real time | 203 |
human populations | 203 |
specific antibody | 202 |
avian infectious | 202 |
iav infection | 202 |
humoral immune | 201 |
severe cases | 201 |
human pathogens | 201 |
risk assessment | 201 |
distress syndrome | 201 |
immunosorbent assay | 201 |
lassa virus | 200 |
cultured cells | 200 |
hcv rna | 200 |
bacterial infection | 200 |
genetic variation | 200 |
commercially available | 199 |
samples collected | 199 |
red blood | 198 |
coat protein | 198 |
different species | 198 |
virus assembly | 198 |
clinical studies | 198 |
vaccine production | 198 |
different types | 197 |
dengue viruses | 197 |
kidney cells | 197 |
diagnostic tests | 197 |
body weight | 197 |
airborne transmission | 196 |
takes place | 196 |
airway epithelial | 196 |
primary infection | 195 |
small molecule | 195 |
molecular characterization | 195 |
gastrointestinal tract | 195 |
conformational changes | 194 |
receptor specificity | 194 |
host defense | 194 |
transmissible gastroenteritis | 193 |
host protein | 193 |
may provide | 193 |
large numbers | 192 |
also observed | 192 |
respiratory diseases | 192 |
better understanding | 192 |
gene transfer | 192 |
data suggest | 192 |
cell receptor | 192 |
new viruses | 192 |
vaccine virus | 191 |
like particle | 191 |
broad spectrum | 191 |
sore throat | 190 |
genome sequencing | 190 |
within days | 190 |
natural reservoir | 190 |
pdm virus | 189 |
international committee | 189 |
million people | 189 |
may contribute | 189 |
hcv replication | 189 |
per cent | 189 |
virus infectivity | 189 |
plaque assay | 189 |
south america | 189 |
case fatality | 188 |
rubella virus | 188 |
dna virus | 188 |
active site | 187 |
natural host | 187 |
signaling pathways | 187 |
north american | 187 |
protein interactions | 187 |
african swine | 187 |
among children | 187 |
antiviral immunity | 186 |
enveloped virus | 186 |
regulatory factor | 186 |
classical swine | 186 |
bovine serum | 186 |
viral polymerase | 185 |
antiviral properties | 185 |
multiplex pcr | 185 |
distemper virus | 185 |
patients infected | 185 |
reservoir hosts | 185 |
animal health | 185 |
antiviral responses | 185 |
positive samples | 185 |
secondary structure | 184 |
drug delivery | 184 |
vertical transmission | 184 |
mass spectrometry | 184 |
virus spread | 184 |
protective efficacy | 183 |
new world | 183 |
statistically significant | 183 |
defective interfering | 183 |
results suggest | 183 |
significantly higher | 183 |
based vaccines | 183 |
dna replication | 183 |
nitric oxide | 183 |
virus titer | 182 |
recombinant vaccinia | 182 |
attenuated vaccines | 182 |
virus species | 182 |
viral mrnas | 182 |
dna vaccines | 182 |
persistently infected | 182 |
rhinovirus infection | 181 |
viral membrane | 181 |
cell type | 181 |
adaptive immunity | 180 |
pr virus | 180 |
high level | 180 |
cell cycle | 180 |
adenovirus type | 180 |
inhibitory effect | 180 |
mg ml | 180 |
cause severe | 180 |
rapid detection | 180 |
conformational change | 180 |
feline infectious | 179 |
recent advances | 179 |
cystic fibrosis | 179 |
lung injury | 179 |
acquired pneumonia | 179 |
binding proteins | 178 |
viral capsid | 178 |
aedes aegypti | 178 |
risk factor | 177 |
molecular basis | 177 |
deep sequencing | 177 |
dengue fever | 177 |
time points | 177 |
chronic obstructive | 177 |
coronavirus infections | 177 |
may play | 176 |
sars virus | 176 |
dependent manner | 176 |
inactivated vaccine | 176 |
disease caused | 176 |
rna genomes | 175 |
genome size | 175 |
modified vaccinia | 175 |
epithelial cell | 175 |
staphylococcus aureus | 175 |
streptococcus pneumoniae | 174 |
infectious peritonitis | 173 |
adverse effects | 173 |
sialic acids | 173 |
disease outbreaks | 173 |
severe influenza | 173 |
specific cd | 173 |
small intestine | 173 |
cell membranes | 172 |
dna vaccine | 172 |
zoonotic diseases | 172 |
one study | 172 |
environmental factors | 172 |
studies using | 172 |
proinflammatory cytokines | 172 |
surface proteins | 171 |
well known | 171 |
based vaccine | 171 |
early stages | 170 |
inflammatory responses | 170 |
molecular epidemiology | 170 |
cynomolgus macaques | 170 |
terminal domain | 170 |
will also | 170 |
drug discovery | 170 |
many different | 170 |
shock protein | 170 |
southeast asia | 169 |
virus types | 168 |
obstructive pulmonary | 168 |
viral life | 168 |
live virus | 168 |
spike glycoprotein | 168 |
post infection | 168 |
coding region | 167 |
taken together | 167 |
serum antibody | 167 |
flying foxes | 167 |
inactivated influenza | 167 |
neu ac | 167 |
cellular receptor | 167 |
rna silencing | 166 |
mouse models | 166 |
viral persistence | 166 |
human adenovirus | 166 |
respiratory failure | 166 |
differential diagnosis | 165 |
vaccine strains | 165 |
national institute | 165 |
pandemic potential | 165 |
different viral | 164 |
cohort study | 164 |
virus activity | 164 |
virus persistence | 164 |
many years | 164 |
critical role | 164 |
bacterial pathogens | 164 |
oxidative stress | 164 |
following infection | 164 |
viral agents | 164 |
cancer cells | 164 |
proteolytic cleavage | 163 |
replication complexes | 163 |
immune complexes | 163 |
also used | 163 |
inactivated vaccines | 163 |
key role | 163 |
electron microscopic | 162 |
several viruses | 162 |
studies suggest | 161 |
southern china | 161 |
major histocompatibility | 161 |
chicken eggs | 161 |
point mutations | 161 |
previously reported | 161 |
virus dna | 160 |
significant differences | 160 |
oral route | 160 |
cerebrospinal fluid | 160 |
mediated endocytosis | 159 |
core protein | 159 |
cytopathic effects | 159 |
high mutation | 159 |
protective immune | 159 |
united kingdom | 159 |
also shown | 159 |
virus using | 158 |
cell activation | 158 |
cell tropism | 158 |
virus growth | 158 |
initiation factor | 157 |
antiviral treatment | 157 |
limited number | 157 |
major cause | 157 |
african green | 157 |
total number | 157 |
small number | 157 |
virus protein | 157 |
early stage | 157 |
nasal swabs | 157 |
fi rst | 157 |
gene product | 157 |
alveolar macrophages | 157 |
fatty acid | 156 |
study showed | 156 |
healthy adults | 156 |
influenza strains | 156 |
human diseases | 156 |
phylogenetic trees | 156 |
insect cells | 156 |
protease inhibitors | 156 |
signal transduction | 156 |
family members | 155 |
also reported | 155 |
cotton rats | 155 |
nuclear export | 155 |
influenza surveillance | 155 |
acute phase | 155 |
prospective study | 155 |
one virus | 155 |
viral pneumonia | 155 |
cell proliferation | 155 |
mediated immunity | 154 |
democratic republic | 154 |
hospitalized patients | 154 |
tcid ml | 154 |
interferon response | 154 |
detection methods | 154 |
viral mrna | 154 |
murine leukemia | 154 |
hospitalized children | 154 |
inclusion bodies | 153 |
acid substitutions | 153 |
virus infected | 153 |
interferon regulatory | 153 |
global health | 153 |
confirmed cases | 153 |
acute viral | 152 |
small molecules | 152 |
viral fitness | 152 |
cytokine storm | 152 |
many cases | 152 |
viral titers | 152 |
evidence suggests | 152 |
genetic characterization | 152 |
feline calicivirus | 152 |
rhesus monkeys | 152 |
fatal cases | 151 |
canine parvovirus | 151 |
influenza season | 151 |
two distinct | 151 |
studies showed | 151 |
maternal antibodies | 151 |
infection induces | 151 |
neutralizing activity | 150 |
clinical characteristics | 150 |
viral strains | 150 |
antigen presentation | 150 |
structural basis | 150 |
two major | 150 |
highly sensitive | 150 |
viral gastroenteritis | 150 |
phase ii | 150 |
laboratory animals | 150 |
dendritic cell | 150 |
i ifns | 150 |
virus pathogenesis | 149 |
ha gene | 149 |
surface glycoproteins | 149 |
pulmonary syndrome | 149 |
simian virus | 149 |
also detected | 149 |
human enteric | 149 |
attenuated influenza | 149 |
heparan sulfate | 149 |
high prevalence | 148 |
emerging viral | 148 |
ifn response | 148 |
novel influenza | 148 |
situ hybridization | 148 |
proteins involved | 148 |
environmental conditions | 148 |
converting enzyme | 147 |
nk cell | 147 |
broad range | 147 |
avian viruses | 147 |
expression levels | 147 |
well plates | 147 |
relatively low | 147 |
human host | 146 |
viral infectivity | 146 |
gene segments | 146 |
become infected | 146 |
tested positive | 146 |
virus diseases | 146 |
major role | 146 |
body fluids | 145 |
different cell | 145 |
virus attachment | 145 |
small rnas | 145 |
lung tissue | 145 |
three times | 145 |
take place | 145 |
also showed | 145 |
cell receptors | 145 |
small interfering | 144 |
alpha beta | 144 |
least two | 144 |
respiratory secretions | 143 |
human herpesvirus | 143 |
potential role | 143 |
remains unclear | 143 |
disease burden | 143 |
virus taxonomy | 143 |
hantavirus pulmonary | 143 |
antigen detection | 143 |
feline leukemia | 143 |
rna polymerases | 143 |
first isolated | 143 |
south korea | 143 |
virus binding | 143 |
care workers | 142 |
viral etiology | 142 |
natural selection | 142 |
genetic information | 142 |
surface antigen | 142 |
mediated immune | 142 |
cytokine production | 142 |
untranslated region | 142 |
new viral | 142 |
encephalomyelitis virus | 142 |
sequence alignment | 141 |
corona virus | 141 |
drug development | 141 |
specific viral | 141 |
identifi ed | 141 |
water samples | 141 |
viral fusion | 141 |
positive results | 141 |
histocompatibility complex | 141 |
pfu ml | 141 |
time point | 141 |
three different | 141 |
ex vivo | 141 |
evolutionary history | 140 |
phylogenetic tree | 140 |
entry site | 139 |
south africa | 139 |
developed countries | 139 |
novel virus | 139 |
foreign gene | 139 |
monkey kidney | 139 |
th century | 139 |
highly contagious | 139 |
see table | 139 |
cellular immunity | 138 |
virus ankara | 138 |
virus neutralization | 138 |
viruses belonging | 138 |
human beings | 138 |
murine norovirus | 138 |
highly effective | 138 |
dans les | 138 |
gold nanoparticles | 138 |
influenza infections | 138 |
blood samples | 138 |
newly discovered | 138 |
results showed | 138 |
last years | 138 |
rsv infections | 138 |
climate change | 138 |
virus vectors | 138 |
human genome | 138 |
viruses including | 137 |
cells via | 137 |
cellular receptors | 137 |
person transmission | 137 |
wild animals | 137 |
total rna | 137 |
viruses detected | 137 |
like protease | 137 |
ebola hemorrhagic | 137 |
viral hepatitis | 137 |
comparative analysis | 137 |
new antiviral | 136 |
genome segments | 136 |
virus outbreak | 136 |
zikv infection | 136 |
inactivated virus | 136 |
influenza hemagglutinin | 136 |
electron microscope | 136 |
vaccine efficacy | 136 |
virus nonstructural | 136 |
presenting cells | 136 |
negative staining | 136 |
viruses using | 136 |
subunit vaccines | 136 |
transmembrane domain | 135 |
two groups | 135 |
host responses | 135 |
high degree | 135 |
binding specificity | 135 |
infections may | 135 |
viruses infecting | 135 |
human primates | 135 |
genomic sequences | 135 |
pcr products | 135 |
might also | 135 |
specific virus | 135 |
innate antiviral | 134 |
time reverse | 134 |
membrane vesicles | 134 |
different strains | 134 |
virus concentration | 134 |
fresh produce | 134 |
gel electrophoresis | 134 |
molecular techniques | 134 |
adult mice | 134 |
emerging pathogens | 133 |
molecular methods | 133 |
homologous recombination | 133 |
virus encephalitis | 133 |
sierra leone | 133 |
natural history | 133 |
cdna clone | 132 |
simultaneous detection | 132 |
fruit bat | 132 |
interferon signaling | 132 |
vaccine design | 132 |
le virus | 132 |
lung disease | 132 |
virus variants | 132 |
infectious agent | 132 |
western blot | 132 |
disease emergence | 132 |
significantly reduced | 132 |
positive selection | 132 |
molecular evolution | 132 |
coding sequence | 132 |
uenza viruses | 132 |
highly virulent | 131 |
host innate | 131 |
stimulated genes | 131 |
infection among | 131 |
transgenic mice | 131 |
viral rnas | 131 |
antiviral compounds | 131 |
virus population | 131 |
specific immune | 131 |
laboratory animal | 131 |
lethal infection | 131 |
tumor cells | 131 |
virus polymerase | 131 |
zoonotic disease | 131 |
single amino | 130 |
mammalian cell | 130 |
hepatocellular carcinoma | 130 |
throat swabs | 130 |
laboratory diagnosis | 130 |
effective vaccines | 130 |
virus capsid | 130 |
day post | 130 |
aerosol transmission | 130 |
virus discovery | 130 |
culture medium | 130 |
significant difference | 130 |
results indicate | 130 |
channel activity | 130 |
type infection | 129 |
virus fusion | 129 |
viral culture | 129 |
cellular membranes | 129 |
genetic variability | 129 |
leaf curl | 129 |
experimental studies | 129 |
quality control | 129 |
negative control | 129 |
high viral | 129 |
sequence identity | 129 |
ifn production | 129 |
neuraminidase inhibitor | 129 |
poorly understood | 128 |
cells expressing | 128 |
fusion activity | 128 |
diseases caused | 128 |
young adults | 128 |
bacterial pneumonia | 128 |
emerging infections | 128 |
virus antigen | 128 |
species barrier | 128 |
airway epithelium | 128 |
viral families | 128 |
virus survival | 127 |
next generation | 127 |
drug administration | 127 |
virus causes | 127 |
blood mononuclear | 127 |
novel human | 127 |
ifn signaling | 127 |
several different | 127 |
avian species | 127 |
high throughput | 127 |
healthcare workers | 127 |
mechanical ventilation | 127 |
functional genomics | 127 |
applied biosystems | 126 |
penaeus monodon | 126 |
new insights | 126 |
whole genome | 126 |
virus induced | 126 |
common cause | 126 |
lethal challenge | 126 |
deficient mice | 126 |
protease inhibitor | 126 |
adverse events | 126 |
virus family | 126 |
clinical presentation | 125 |
different virus | 125 |
polymerase activity | 125 |
acidic ph | 125 |
may develop | 125 |
first step | 125 |
surveillance system | 125 |
gastroenteritis virus | 125 |
newly synthesized | 125 |
virus influenza | 124 |
see also | 124 |
viral detection | 124 |
inhibitory activity | 124 |
may help | 124 |
clinical course | 124 |
zoonotic transmission | 124 |
pseudorabies virus | 124 |
embryonated eggs | 124 |
viral diversity | 123 |
interfering rna | 123 |
may affect | 123 |
two types | 123 |
children aged | 123 |
frequently detected | 123 |
old world | 123 |
virus expressing | 123 |
fatal disease | 123 |
virus release | 123 |
subunit vaccine | 123 |
viruses also | 123 |
much less | 122 |
virus life | 122 |
newly identified | 122 |
measles vaccine | 122 |
chronic infection | 122 |
tissue damage | 122 |
phage display | 122 |
infectious dose | 122 |
give rise | 122 |
many countries | 122 |
interspecies transmission | 122 |
proteolytic processing | 122 |
first reported | 122 |
human serum | 122 |
viruses cause | 121 |
suckling mice | 121 |
also present | 121 |
antiviral agent | 121 |
infections caused | 121 |
viral genomic | 121 |
natural hosts | 121 |
rapid diagnosis | 121 |
binding affinity | 121 |
protein vp | 121 |
recognition receptors | 121 |
viral spread | 121 |
liver disease | 121 |
reporter gene | 121 |
nuclear import | 121 |
cd cells | 121 |
single virus | 120 |
gene delivery | 120 |
embryonated chicken | 120 |
may represent | 120 |
hemagglutination inhibition | 120 |
attenuated virus | 120 |
pattern recognition | 120 |
persistent infections | 120 |
vast majority | 120 |
fatty acids | 120 |
rna binding | 120 |
cleavage sites | 120 |
cellular protein | 120 |
rna segments | 120 |
origin influenza | 120 |
respiratory droplets | 120 |
index case | 119 |
herpes viruses | 119 |
detection limit | 119 |
bronchial epithelial | 119 |
viral population | 119 |
cells may | 119 |
care unit | 119 |
marburg viruses | 119 |
negatively stained | 119 |
cell spread | 119 |
haemophilus influenzae | 119 |
lymphoid tissues | 119 |
secretory pathway | 119 |
vaccine vectors | 119 |
epidemiological studies | 119 |
bluetongue virus | 119 |
specific antiviral | 119 |
wastewater treatment | 119 |
des virus | 119 |
water quality | 118 |
aedes albopictus | 118 |
interfering rnas | 118 |
coronavirus spike | 118 |
common ancestor | 118 |
culture systems | 118 |
attenuated live | 118 |
current knowledge | 118 |
expression systems | 118 |
brain barrier | 118 |
internal ribosome | 118 |
genetic analysis | 118 |
less likely | 118 |
mouse strains | 118 |
neurological disease | 118 |
phase iii | 118 |
ribosome entry | 118 |
cytoplasmic domain | 118 |
two main | 118 |
protective equipment | 117 |
encephalomyocarditis virus | 117 |
emerging diseases | 117 |
study group | 117 |
also important | 117 |
viral vector | 117 |
much higher | 117 |
cell epitopes | 117 |
coding regions | 117 |
reactive oxygen | 117 |
nuclear localization | 117 |
also occur | 117 |
terminal region | 117 |
igg antibodies | 117 |
infected host | 117 |
dengue hemorrhagic | 117 |
en el | 117 |
among different | 117 |
severe pneumonia | 116 |
protein sequences | 116 |
poliovirus rna | 116 |
biological properties | 116 |
activated protein | 116 |
respiratory specimens | 116 |
salivary glands | 116 |
emerging virus | 116 |
may become | 116 |
children hospitalized | 116 |
biosafety level | 116 |
airway inflammation | 116 |
phylogenetic analyses | 116 |
viral species | 116 |
clinical practice | 116 |
vaccine vector | 115 |
viral attachment | 115 |
disease outbreak | 115 |
endothelial cell | 115 |
interferon production | 115 |
large amounts | 115 |
effective vaccine | 115 |
dependent enhancement | 115 |
heart disease | 115 |
du virus | 115 |
throughput sequencing | 115 |
highly susceptible | 115 |
protective effect | 115 |
simian immunodeficiency | 115 |
human rhinoviruses | 115 |
higher levels | 114 |
van der | 114 |
rna molecules | 114 |
infant mice | 114 |
small animal | 114 |
viral surface | 114 |
cell growth | 114 |
polymerase complex | 114 |
strains isolated | 114 |
research council | 114 |
also cause | 114 |
universal influenza | 114 |
serine protease | 114 |
recombination events | 114 |
beta interferon | 114 |
ns gene | 114 |
essential role | 114 |
multiple viruses | 114 |
primary human | 114 |
murine hepatitis | 114 |
long term | 114 |
cellular factors | 113 |
leading cause | 113 |
infection occurs | 113 |
serological tests | 113 |
infectious particles | 113 |
acute lower | 113 |
lymph node | 113 |
novel antiviral | 113 |
dna sequences | 113 |
reservoir host | 113 |
sequence similarity | 113 |
gene sequences | 113 |
hantaan virus | 113 |
whole virus | 113 |
antiviral state | 113 |
antibody production | 113 |
better understand | 113 |
common respiratory | 113 |
hbv infection | 113 |
immunodeficient mice | 113 |
febrile illness | 113 |
cytoplasmic tail | 113 |
virus research | 113 |
may include | 113 |
different mechanisms | 113 |
inflammatory cells | 112 |
first described | 112 |
rv infection | 112 |
differentially expressed | 112 |
human lung | 112 |
adhesion molecule | 112 |
inhibit viral | 112 |
ha protein | 112 |
east asia | 112 |
viral contamination | 112 |
immunocompetent mice | 112 |
crucial role | 112 |
results obtained | 112 |
mouse colonies | 112 |
knockout mice | 111 |
molecular detection | 111 |
creative commons | 111 |
broadly neutralizing | 111 |
dans le | 111 |
body temperature | 111 |
host population | 111 |
transmission electron | 111 |
previous study | 111 |
similar results | 111 |
rotavirus infection | 111 |
virion assembly | 111 |
productive infection | 111 |
surface protein | 111 |
virus removal | 111 |
diagnostic methods | 111 |
sarcoma virus | 111 |
personal protective | 111 |
pcr amplification | 111 |
convalescent plasma | 111 |
acute gastroenteritis | 111 |
long time | 110 |
live vaccines | 110 |
randomized controlled | 110 |
respiratory epithelium | 110 |
viral components | 110 |
will help | 110 |
table i | 110 |
negatively charged | 110 |
ace receptor | 110 |
oral fluid | 110 |
positively charged | 110 |
viruses causing | 110 |
single dose | 110 |
murine coronavirus | 110 |
data indicate | 110 |
respiratory epithelial | 110 |
data analysis | 110 |
see chapter | 110 |
well tolerated | 110 |
veterinary medicine | 110 |
skin lesions | 110 |
causative agents | 110 |
dsrna viruses | 110 |
current status | 109 |
tissue samples | 109 |
high sensitivity | 109 |
rna viral | 109 |
immune complex | 109 |
high affinity | 109 |
certain viruses | 109 |
antibody levels | 109 |
viral evolution | 109 |
infected pigs | 109 |
transmission routes | 108 |
maximum likelihood | 108 |
viral vaccines | 108 |
viruses associated | 108 |
acid changes | 108 |
oxygen species | 108 |
also demonstrated | 108 |
may explain | 108 |
virus will | 108 |
reassortant viruses | 108 |
combination therapy | 108 |
among others | 108 |
log reduction | 107 |
host cellular | 107 |
protect mice | 107 |
relatively high | 107 |
supportive care | 107 |
mammalian species | 107 |
zoonotic potential | 107 |
respiratory samples | 107 |
novel host | 107 |
may serve | 107 |
among patients | 107 |
viral hemorrhagic | 107 |
past years | 107 |
attenuated vaccine | 107 |
early life | 107 |
newly emerging | 107 |
infections among | 106 |
based assays | 106 |
mouse brain | 106 |
many studies | 106 |
specific primers | 106 |
adenovirus infection | 106 |
vaccinated animals | 106 |
complement fixation | 106 |
latent infection | 106 |
antigenic shift | 106 |
two decades | 106 |
smallpox vaccine | 106 |
possible role | 106 |
infection rate | 106 |
serological evidence | 106 |
inhibitory effects | 106 |
symptom onset | 106 |
coding sequences | 106 |
healthy individuals | 106 |
rsv disease | 106 |
pet birds | 106 |
severe illness | 105 |
respiratory illnesses | 105 |
virus isolate | 105 |
new human | 105 |
future studies | 105 |
varicella zoster | 105 |
mumps virus | 105 |
influenza viral | 105 |
among humans | 105 |
pathological changes | 105 |
virucidal activity | 105 |
acute otitis | 105 |
high concentrations | 105 |
preventive measures | 105 |
vitro studies | 105 |
west african | 105 |
copy number | 105 |
see section | 105 |
early detection | 105 |
polymerase ii | 105 |
distantly related | 105 |
viral metagenomics | 105 |
like symptoms | 104 |
ebov infection | 104 |
etiologic agent | 104 |
initial infection | 104 |
influenza pandemics | 104 |
genetic engineering | 104 |
genes encoding | 104 |
buffered saline | 104 |
dna synthesis | 104 |
environmental samples | 104 |
golgi apparatus | 104 |
virus also | 104 |
close proximity | 104 |
well documented | 104 |
near future | 104 |
well established | 104 |
virus nucleoprotein | 103 |
human virus | 103 |
nonenveloped viruses | 103 |
maternal antibody | 103 |
flying fox | 103 |
nonhuman primate | 103 |
expression system | 103 |
spanish flu | 103 |
nasal mucosa | 103 |
antiviral signaling | 103 |
delivery systems | 103 |
clinical outcome | 103 |
ssrna viruses | 102 |
new zealand | 102 |
associated coronavirus | 102 |
human norovirus | 102 |
mutant spectrum | 102 |
tanguticum nanoparticles | 102 |
host factor | 102 |
therapeutic agents | 102 |
small rna | 102 |
virus induces | 102 |
high frequency | 102 |
nasal secretions | 102 |
important factor | 102 |
will provide | 102 |
first report | 102 |
sample collection | 102 |
general population | 102 |
bronchoalveolar lavage | 102 |
proteins may | 102 |
viral transmission | 102 |
movement protein | 102 |
ill patients | 101 |
virus sequences | 101 |
significantly lower | 101 |
virus interactions | 101 |
viral quasispecies | 101 |
copies ml | 101 |
vaccine viruses | 101 |
viral glycoprotein | 101 |
genetic reassortment | 101 |
several days | 101 |
findings suggest | 101 |
surface receptors | 101 |
also identified | 101 |
associated protein | 101 |
determined using | 101 |
antiviral therapies | 101 |
several years | 101 |
data set | 101 |
etiological agent | 101 |
ebola viruses | 100 |
recombinant mva | 100 |
sequence homology | 100 |
viruses use | 100 |
specific pathogen | 100 |
mutant viruses | 100 |
blood vessels | 100 |
indirect contact | 100 |
effective antiviral | 100 |
immune status | 100 |
recombinant proteins | 100 |
porcine circovirus | 100 |
last decade | 100 |
vertebrate hosts | 100 |
virus receptor | 100 |
matrix completion | 100 |
viruses circulating | 100 |
transmembrane protein | 100 |
interstitial pneumonia | 100 |
gene silencing | 100 |
viruses will | 100 |
natural infections | 100 |
antiviral immune | 100 |
golgi complex | 100 |
viral titer | 99 |
competing interests | 99 |
ebola outbreak | 99 |
foodborne viruses | 99 |
nuclear factor | 99 |
also play | 99 |
new coronavirus | 99 |
mucous membranes | 99 |
antiviral innate | 99 |
virus associated | 99 |
national institutes | 99 |
acute bronchiolitis | 99 |
economic losses | 99 |
family paramyxoviridae | 99 |
antiviral action | 99 |
coronavirus oc | 99 |
unpublished data | 99 |
humoral immunity | 99 |
standard deviation | 99 |
food safety | 99 |
associated herpesvirus | 99 |
low level | 99 |
gene encoding | 99 |
igg antibody | 98 |
disease symptoms | 98 |
antiviral strategies | 98 |
existing immunity | 98 |
challenge virus | 98 |
mosquito cells | 98 |
potential therapeutic | 98 |
genetically modified | 98 |
avian infl | 98 |
virus adsorption | 98 |
experimental conditions | 98 |
consensus sequence | 98 |
candidate vaccines | 98 |
disease may | 98 |
signifi cant | 98 |
hematopoietic stem | 98 |
acute lung | 98 |
canine kidney | 98 |
complex formation | 98 |
will continue | 98 |
quantitative pcr | 98 |
virus glycoproteins | 98 |
intestinal tract | 98 |
natural reservoirs | 98 |
fetal bovine | 98 |
forming units | 98 |
les virus | 97 |
hiv aids | 97 |
factors associated | 97 |
fluorescent protein | 97 |
entry inhibitors | 97 |
virus host | 97 |
antigenic variation | 97 |
infected human | 97 |
hepatitis viruses | 97 |
lung epithelial | 97 |
cell transplant | 97 |
european countries | 97 |
genome organization | 97 |
codon usage | 97 |
metapneumovirus infection | 97 |
protects mice | 97 |
fecal samples | 97 |
high rate | 97 |
specific igg | 97 |
coronavirus replication | 97 |
nested pcr | 97 |
many viral | 97 |
remains unknown | 96 |
mammalian viruses | 96 |
vaccine delivery | 96 |
sin nombre | 96 |
infection cycle | 96 |
recombinant protein | 96 |
candidate vaccine | 96 |
passive immunization | 96 |
flow cytometry | 96 |
virus populations | 96 |
wnv infection | 96 |
vaccination strategies | 96 |
influenza epidemics | 96 |
often associated | 96 |
another example | 96 |
experimental data | 96 |
critically ill | 96 |
highly specific | 96 |
monkeypox virus | 96 |
infection rates | 96 |
one hand | 96 |
scid mice | 96 |
gross lesions | 96 |
virus vp | 95 |
thymidine kinase | 95 |
mycobacterium tuberculosis | 95 |
minute virus | 95 |
live vaccine | 95 |
glycosylation sites | 95 |
fatality rates | 95 |
surface glycoprotein | 95 |
bovine herpesvirus | 95 |
white spot | 95 |
also possible | 95 |
host immunity | 95 |
medical research | 95 |
several weeks | 95 |
virulence factors | 95 |
single stranded | 95 |
animal studies | 95 |
human immune | 95 |
associated viruses | 95 |
statistical analysis | 95 |
cell wall | 95 |
vaccines based | 95 |
virus gene | 95 |
virus groups | 95 |
immune cell | 95 |
analysis revealed | 95 |
selective pressure | 95 |
experimental infections | 95 |
clinical use | 95 |
hemorrhagic fevers | 95 |
past decade | 95 |
plasmid dna | 95 |
infection results | 94 |
mitochondrial function | 94 |
linked sialic | 94 |
clinical management | 94 |
autoimmune diseases | 94 |
protein interaction | 94 |
breast cancer | 94 |
vivo studies | 94 |
chez les | 94 |
infectious viruses | 94 |
control study | 94 |
potential antiviral | 94 |
mutant virus | 94 |
virus factories | 94 |
emerging zoonotic | 94 |
brain tissue | 94 |
gold standard | 94 |
metagenomic analysis | 94 |
rna helicase | 94 |
control strategies | 94 |
new influenza | 94 |
sars cov | 94 |
glial cells | 94 |
disease transmission | 94 |
interfering particles | 94 |
integral membrane | 94 |
respiratory system | 94 |
pandemic strain | 94 |
ist die | 93 |
health authorities | 93 |
jc virus | 93 |
supplementary material | 93 |
intermediate host | 93 |
human macrophages | 93 |
first identified | 93 |
infect cells | 93 |
will allow | 93 |
ns proteins | 93 |
central africa | 93 |
full length | 93 |
virus identification | 93 |
cell leukemia | 93 |
infected person | 93 |
days later | 93 |
negative stain | 93 |
relative abundance | 93 |
lipid metabolism | 93 |
multiple sequence | 93 |
outer membrane | 93 |
survival rate | 93 |
identifi cation | 93 |
research complications | 93 |
defense mechanisms | 93 |
infection causes | 93 |
antiviral defense | 93 |
blood cell | 92 |
global burden | 92 |
pediatric patients | 92 |
single nucleotide | 92 |
eukaryotic cells | 92 |
data sets | 92 |
movement proteins | 92 |
every year | 92 |
high titers | 92 |
st century | 92 |
surface area | 92 |
accessory proteins | 92 |
pandemic viruses | 92 |
diarrhoea virus | 92 |
detection rate | 92 |
late endosomes | 92 |
migratory birds | 92 |
blood donors | 92 |
quantum dots | 92 |
cytomegalovirus infection | 92 |
human hepatitis | 92 |
well understood | 92 |
transmitted via | 91 |
dsdna viruses | 91 |
nasal swab | 91 |
endosomal membrane | 91 |
particle size | 91 |
environmental surfaces | 91 |
conserved among | 91 |
small round | 91 |
zoonotic pathogens | 91 |
type viruses | 91 |
killer cells | 91 |
important roles | 91 |
bovine respiratory | 91 |
lung function | 91 |
based methods | 91 |
bl mice | 91 |
studies indicate | 91 |
antigenic sites | 91 |
clinical diagnosis | 91 |
thin sections | 91 |
negative strand | 91 |
honey bee | 91 |
viral genetic | 91 |
mediated antiviral | 91 |
ubiquitin ligase | 91 |
large dna | 91 |
data obtained | 91 |
two proteins | 91 |
cells using | 91 |
green monkey | 91 |
protein structure | 91 |
lymphoid tissue | 91 |
virus group | 91 |
throughput screening | 91 |
factors affecting | 90 |
expression vector | 90 |
sample preparation | 90 |
significantly different | 90 |
viruses present | 90 |
increasing number | 90 |
also called | 90 |
interferon induction | 90 |
ctl responses | 90 |
viral variants | 90 |
cellular entry | 90 |
often used | 90 |
human cell | 90 |
diabetes mellitus | 90 |
transmission via | 90 |
allantoic fluid | 90 |
cytokine responses | 90 |
i interferons | 90 |
genetically engineered | 90 |
whole blood | 90 |
three viruses | 90 |
ifn induction | 90 |
virus vector | 90 |
molecular mimicry | 90 |
endemic areas | 90 |
cell monolayers | 90 |
ctl response | 89 |
several viral | 89 |
viral populations | 89 |
adult patients | 89 |
higher risk | 89 |
spot syndrome | 89 |
clinical data | 89 |
recent work | 89 |
common colds | 89 |
viral diagnosis | 89 |
induced apoptosis | 89 |
resistant viruses | 89 |
foamy virus | 89 |
different stages | 89 |
recent report | 89 |
cell lysis | 89 |
yellow head | 89 |
million deaths | 89 |
negative results | 89 |
cotton rat | 89 |
case report | 89 |
aged years | 89 |
study using | 89 |
virus neuraminidase | 89 |
cd cd | 89 |
kidney cell | 89 |
new vaccines | 89 |
vice versa | 89 |
drug repurposing | 89 |
calf serum | 89 |
temperature sensitivity | 88 |
alveolar epithelial | 88 |
rna extraction | 88 |
basic protein | 88 |
hand hygiene | 88 |
study period | 88 |
cellular processes | 88 |
antibodies directed | 88 |
one health | 88 |
surface expression | 88 |
virus replicates | 88 |
protein gene | 88 |
acid binding | 88 |
therapeutic strategies | 88 |
cell function | 88 |
clinical development | 88 |
intravenous immunoglobulin | 88 |
progeny virus | 88 |
protein ns | 88 |
new species | 88 |
arthropod vectors | 88 |
per day | 88 |
subcellular localization | 88 |
virus propagation | 88 |
year old | 88 |
viruses like | 88 |
virus subtypes | 88 |
da asma | 88 |
functional analysis | 88 |
will require | 88 |
antibody titer | 88 |
host gene | 88 |
signal peptide | 88 |
antiviral efficacy | 88 |
er stress | 87 |
low pathogenic | 87 |
immune systems | 87 |
lethal mutagenesis | 87 |
using different | 87 |
porcine respiratory | 87 |
endogenous retroviruses | 87 |
human pathogen | 87 |
human clinical | 87 |
animal cell | 87 |
virus receptors | 87 |
probably due | 87 |
much lower | 87 |
intranasal inoculation | 87 |
adaptor protein | 87 |
several months | 87 |
spanish influenza | 87 |
bei der | 87 |
asian countries | 87 |
molecular patterns | 87 |
genbank accession | 87 |
vp protein | 87 |
acute hepatitis | 87 |
escape mutants | 87 |
living cells | 87 |
severe clinical | 87 |
least three | 87 |
ebov gp | 86 |
smallpox vaccination | 86 |
severe fever | 86 |
analysis using | 86 |
hsct recipients | 86 |
rna sequences | 86 |
two strains | 86 |
next pandemic | 86 |
selection pressure | 86 |
may vary | 86 |
methods used | 86 |
host antiviral | 86 |
per ml | 86 |
pseudomonas aeruginosa | 86 |
vaccinia viruses | 86 |
fatal human | 86 |
lethal disease | 86 |
available data | 86 |
mucosal immunity | 86 |
modified live | 86 |
likely due | 86 |
plaque reduction | 86 |
human embryonic | 86 |
transcription polymerase | 86 |
currently used | 86 |
twentieth century | 86 |
human parvovirus | 85 |
rhinovirus infections | 85 |
entry process | 85 |
saharan africa | 85 |
lipid envelope | 85 |
biomedical research | 85 |
uninfected cells | 85 |
dromedary camels | 85 |
immune globulin | 85 |
complete protection | 85 |
foreign genes | 85 |
cellular rna | 85 |
population size | 85 |
vectored vaccines | 85 |
quantitative real | 85 |
lactate dehydrogenase | 85 |
manufacturing process | 85 |
plasma cells | 85 |
highly attenuated | 85 |
contaminated water | 85 |
virus circulation | 85 |
virus core | 85 |
particular interest | 85 |
nuclear translocation | 85 |
mechanisms involved | 85 |
national research | 85 |
stainless steel | 85 |
vaccine expressing | 85 |
metagenomic sequencing | 85 |
mammalian hosts | 85 |
acid extraction | 85 |
virus bronchiolitis | 85 |
free virus | 84 |
resistance mutations | 84 |
infected humans | 84 |
emergency department | 84 |
cap structure | 84 |
biological materials | 84 |
high virulence | 84 |
within hours | 84 |
serum antibodies | 84 |
host genes | 84 |
genetic variants | 84 |
cellular membrane | 84 |
inflammatory mediators | 84 |
thermo fisher | 84 |
study conducted | 84 |
widely distributed | 84 |
nipah viruses | 84 |
therapeutic potential | 84 |
factor receptor | 84 |
virus among | 84 |
per se | 84 |
accession numbers | 84 |
immune electron | 84 |
pcr detection | 84 |
cervical cancer | 84 |
rsv bronchiolitis | 84 |
chronically infected | 84 |
affected animals | 84 |
enveloped rna | 84 |
acid amplification | 84 |
will likely | 84 |
cell interactions | 84 |
aquatic birds | 84 |
viruses among | 84 |
lesser extent | 83 |
natural products | 83 |
thrombocytopenia syndrome | 83 |
enzymatic activity | 83 |
acquired immunodeficiency | 83 |
genomic sequence | 83 |
family flaviviridae | 83 |
blood transfusion | 83 |
high morbidity | 83 |
differential expression | 83 |
passive transfer | 83 |
phylogenetic relationships | 83 |
immunodeficiency syndrome | 83 |
darby canine | 83 |
older adults | 83 |
antigenically related | 83 |
potent antiviral | 83 |
infected birds | 83 |
latently infected | 83 |
study design | 83 |
viral safety | 83 |
years later | 83 |
host genome | 83 |
factors involved | 83 |
associated molecular | 83 |
first case | 83 |
pandemic preparedness | 83 |
drug design | 83 |
renal syndrome | 83 |
infected persons | 83 |
important cause | 83 |
vlp vaccines | 82 |
viral growth | 82 |
family coronaviridae | 82 |
linked glycosylation | 82 |
culture system | 82 |
virus load | 82 |
new hosts | 82 |
may induce | 82 |
systemic infection | 82 |
animal virus | 82 |
virus clearance | 82 |
binding properties | 82 |
igm antibodies | 82 |
resistant strains | 82 |
induced asthma | 82 |
side chains | 82 |
vaccination programs | 82 |
clinical outcomes | 82 |
feline coronavirus | 82 |
informed consent | 82 |
unclear whether | 82 |
viral isolates | 82 |
rsv vaccine | 82 |
increased susceptibility | 82 |
genes involved | 82 |
kda protein | 82 |
neurological signs | 82 |
organ cultures | 82 |
viral pathogen | 82 |
supplementary table | 82 |
membrane structures | 82 |
vascular endothelial | 82 |
vaccinated mice | 82 |
interferon alpha | 82 |
significant reduction | 82 |
disease associated | 82 |
detection rates | 82 |
immune signaling | 81 |
specific ctl | 81 |
novel viral | 81 |
long periods | 81 |
may allow | 81 |
induced cell | 81 |
lyme disease | 81 |
known viruses | 81 |
retrospective study | 81 |
protein inhibits | 81 |
graphene oxide | 81 |
advisory committee | 81 |
health concern | 81 |
vaccine protects | 81 |
ferret model | 81 |
mice may | 81 |
neurological symptoms | 81 |
serial dilutions | 81 |
two weeks | 81 |
prevent infection | 81 |
mesenchymal stem | 81 |
transmission occurs | 81 |
cellular functions | 80 |
culture media | 80 |
three groups | 80 |
lipid bilayers | 80 |
young infants | 80 |
virus antigens | 80 |
virus infects | 80 |
fold higher | 80 |
protein levels | 80 |
recombinant dna | 80 |
plasmacytoid dendritic | 80 |
hpai viruses | 80 |
cell transmission | 80 |
herd immunity | 80 |
otherwise healthy | 80 |
cell biology | 80 |
fever viruses | 80 |
animal reservoirs | 80 |
asymptomatic infection | 80 |
antigenically distinct | 80 |
rodent species | 80 |
enteric virus | 80 |
lymphotropic virus | 80 |
passive immunity | 80 |
binding pocket | 80 |
particularly important | 80 |
influenza activity | 80 |
rousettus aegyptiacus | 80 |
reported cases | 80 |
internal genes | 80 |
molecular cloning | 80 |
also associated | 79 |
chemokine receptor | 79 |
recombinant vaccine | 79 |
evolutionary genetics | 79 |
genetic changes | 79 |
coronavirus associated | 79 |
another important | 79 |
rational design | 79 |
nude mice | 79 |
asymptomatic infections | 79 |
first year | 79 |
viruses identified | 79 |
mers coronavirus | 79 |
viruses replicate | 79 |
human viral | 79 |
based assay | 79 |
transport medium | 79 |
diagnostic laboratories | 79 |
vaccine based | 79 |
fold increase | 79 |
may contain | 79 |
specific viruses | 79 |
secondary infections | 79 |
transmission dynamics | 79 |
oral administration | 79 |
different regions | 79 |
urgent need | 79 |
children younger | 79 |
recently reported | 79 |
virus specific | 79 |
clinical illness | 79 |
ng ml | 79 |
lung transplant | 78 |
cellular mrnas | 78 |
lipid raft | 78 |
marrow transplant | 78 |
acid substitution | 78 |
vivi disease | 78 |
contaminated food | 78 |
subgenomic rna | 78 |
borne diseases | 78 |
life technologies | 78 |
sea water | 78 |
final concentration | 78 |
may increase | 78 |
vitro antiviral | 78 |
protein complexes | 78 |
geographic distribution | 78 |
blood products | 78 |
respiratory coronavirus | 78 |
crystal structures | 78 |
protein nanocages | 78 |
different host | 78 |
direct interaction | 78 |
organ systems | 78 |
early studies | 78 |
resistant influenza | 78 |
previously unknown | 78 |
white blood | 77 |
coronavirus nl | 77 |
experimental inoculation | 77 |
nasopharyngeal aspirates | 77 |
sequencing data | 77 |
natural foci | 77 |
domestic poultry | 77 |
frequently used | 77 |
bat viruses | 77 |
agarose gel | 77 |
may act | 77 |
avian flu | 77 |
comprehensive review | 77 |
lung tissues | 77 |
human enterovirus | 77 |
study demonstrated | 77 |
replication sites | 77 |
pg ml | 77 |
rous sarcoma | 77 |
organ failure | 77 |
diagnostic testing | 77 |
infections due | 77 |
viral assembly | 77 |
lung slices | 77 |
synthetic peptides | 77 |
swine flu | 77 |
acquired immune | 77 |
infectious cdna | 77 |
lipid membrane | 77 |
economic impact | 77 |
immune recognition | 77 |
affecting humans | 77 |
proteins encoded | 77 |
variola virus | 77 |
borne flaviviruses | 77 |
immunodefi ciency | 77 |
highly divergent | 77 |
generated using | 77 |
cell infection | 76 |
serological studies | 76 |
replication fidelity | 76 |
complement activation | 76 |
world war | 76 |
virus cell | 76 |
using recombinant | 76 |
goat anti | 76 |
nlrp inflammasome | 76 |
virus recovery | 76 |
infection caused | 76 |
nasopharyngeal swabs | 76 |
stimulated gene | 76 |
mixed infections | 76 |
first wave | 76 |
infect dis | 76 |
murine model | 76 |
disease surveillance | 76 |
times higher | 76 |
recombinant human | 76 |
false positive | 76 |
virus via | 76 |
cell adhesion | 76 |
therapeutic efficacy | 76 |
detected using | 76 |
virus neutralizing | 76 |
head virus | 76 |
health officials | 76 |
treatment options | 76 |
including humans | 76 |
host interaction | 75 |
immune deficiency | 75 |
multiple viral | 75 |
disease viruses | 75 |
virus detected | 75 |
spongiform encephalopathy | 75 |
hydrogen peroxide | 75 |
nasal discharge | 75 |
pathogenic bacteria | 75 |
positive control | 75 |
tract illness | 75 |
hsv infection | 75 |
dna genome | 75 |
animals may | 75 |
common viruses | 75 |
circulating strains | 75 |
including influenza | 75 |
may facilitate | 75 |
relatively small | 75 |
highly variable | 75 |
analysis showed | 75 |
extensively studied | 75 |
viral capsids | 75 |
flavivirus infection | 75 |
experimental evidence | 75 |
nombre virus | 75 |
genetic stability | 75 |
high incidence | 75 |
risk groups | 75 |
induced disease | 75 |
previously published | 75 |
new vaccine | 75 |
inducible gene | 75 |
genetic recombination | 75 |
herpes zoster | 75 |
endocytic pathway | 75 |
resistant virus | 75 |
molecule inhibitors | 74 |
study also | 74 |
passive immunotherapy | 74 |
different subtypes | 74 |
three types | 74 |
clinical isolates | 74 |
population density | 74 |
dengue infection | 74 |
disease pathogenesis | 74 |
serum albumin | 74 |
pathogenic influenza | 74 |
five years | 74 |
distilled water | 74 |
mild disease | 74 |
neonatal mice | 74 |
data collection | 74 |
major capsid | 74 |
currently circulating | 74 |
viral inactivation | 74 |
highly efficient | 74 |
effective treatment | 74 |
human blood | 74 |
medical care | 74 |
nuclear membrane | 74 |
virus nucleocapsid | 74 |
also affect | 74 |
antigenic variants | 74 |
egg production | 74 |
studies will | 74 |
plant rna | 74 |
cell immunity | 74 |
progeny virions | 74 |
virus antibodies | 74 |
developed using | 74 |
middle ear | 74 |
diagnostic laboratory | 74 |
green monkeys | 74 |
step rt | 74 |
severe covid | 74 |
severity score | 74 |
older children | 74 |
enter cells | 74 |
will need | 74 |
kg day | 74 |
new generation | 74 |
serial passage | 74 |
resistant mutants | 73 |
iii ifns | 73 |
infecting humans | 73 |
chikungunya fever | 73 |
virus genetic | 73 |
sexual transmission | 73 |
global influenza | 73 |
studies show | 73 |
successfully used | 73 |
expression vectors | 73 |
intracellular transport | 73 |
chronic disease | 73 |
acute asthma | 73 |
human volunteers | 73 |
cause respiratory | 73 |
also provide | 73 |
viral translation | 73 |
central african | 73 |
tissue cultures | 73 |
liver cells | 73 |
host specificity | 73 |
virol doi | 73 |
recently identified | 73 |
zaire ebolavirus | 73 |
specific host | 73 |
analyzed using | 73 |
logistic regression | 73 |
aug codon | 73 |
studies conducted | 73 |
well plate | 73 |
cellular dna | 73 |
hours post | 73 |
viral structural | 73 |
challenge infection | 73 |
complete genomes | 73 |
virus surface | 73 |
large scale | 73 |
positive sense | 73 |
indirect immunofluorescence | 73 |
pig model | 73 |
recently developed | 73 |
recent evidence | 73 |
human sera | 73 |
experimental animals | 73 |
rhesus macaque | 73 |
viral sequence | 73 |
drug targets | 73 |
less severe | 73 |
viruses date | 73 |
virus membrane | 73 |
puerto rico | 73 |
using reverse | 73 |
proton channel | 73 |
disease prevention | 73 |
virus genomic | 73 |
accession number | 72 |
antibody complexes | 72 |
personal communication | 72 |
rna degradation | 72 |
human pathogenic | 72 |
small size | 72 |
psittacine birds | 72 |
smallpox virus | 72 |
social distancing | 72 |
vaccine effectiveness | 72 |
messenger rna | 72 |
clinical study | 72 |
coronavirus hku | 72 |
less frequently | 72 |
host mrnas | 72 |
highly infectious | 72 |
viruses within | 72 |
clinical significance | 72 |
two doses | 72 |
promising results | 72 |
oral cavity | 72 |
mortality associated | 72 |
olfactory bulb | 72 |
coxsackie virus | 72 |
viral co | 72 |
approved drugs | 72 |
neutralizing human | 72 |
yersinia pestis | 72 |
fusion process | 72 |
complete nucleotide | 72 |
population dynamics | 71 |
primary cells | 71 |
preclinical studies | 71 |
intermediate hosts | 71 |
stop codon | 71 |
retinoic acid | 71 |
henipavirus infection | 71 |
vp vp | 71 |
fi tness | 71 |
human subjects | 71 |
viruses might | 71 |
recent developments | 71 |
days postinfection | 71 |
central role | 71 |
epidemiological data | 71 |
rna segment | 71 |
infection model | 71 |
biological functions | 71 |
antiretroviral therapy | 71 |
length genome | 71 |
mast cells | 71 |
encephalitis viruses | 71 |
evolutionary relationships | 71 |
viruses expressing | 71 |
isothermal amplification | 71 |
pivotal role | 71 |
mechanisms underlying | 71 |
various viruses | 71 |
relationships among | 71 |
genetic background | 71 |
aichi virus | 71 |
last two | 71 |
side chain | 71 |
listeria monocytogenes | 71 |
hcv ns | 71 |
heart failure | 71 |
high fever | 71 |
infected individual | 71 |
protein complex | 71 |
including human | 71 |
potential use | 71 |
per cell | 71 |
equine encephalomyelitis | 70 |
fluorescent antibody | 70 |
th responses | 70 |
gene sequence | 70 |
healthy children | 70 |
using real | 70 |
life cycles | 70 |
viral diarrhoea | 70 |
time course | 70 |
short period | 70 |
virus containing | 70 |
virus subtype | 70 |
env gene | 70 |
factor alpha | 70 |
biological activity | 70 |
effector functions | 70 |
leukaemia virus | 70 |
nuclear pore | 70 |
bovine coronavirus | 70 |
hsp inhibitors | 70 |
lopinavir ritonavir | 70 |
functional receptor | 70 |